Impact Receives US FDA's IND Clearance for IMP9064 to Treat Solid Tumor
Shots:
- The company will initiate the P-I/II dose-escalation & expansion study to evaluate the safety, PK & anti-tumor activities of IMP9064 as monothx. & in combination with Senaparib in patients with advanced solid tumors
- In preclinical studies, IMP9064 was a highly potent ATR inhibitor & selective against other kinases & showed high activities in several ATM-deficient cell lines compared to reference compounds in xenograft in vivo models
- IMP9064 is an ATR inhibitor while Senaparib is a PARP inhibitor which has been evaluated in multiple clinical studies globally. The company has designed a clinical strategy for IMP9064 to advance clinical development & provides benefits to patients globally
toRef: PRNewswire | Image: Crunchbase
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com